These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 38439728)

  • 61. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A; Gniadecki R
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Delayed response of oral pemphigus vulgaris to rituximab treatment.
    Niedermeier A; Wörl P; Barth S; Schuler G; Hertl M
    Eur J Dermatol; 2006; 16(3):266-70. PubMed ID: 16709491
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review.
    Tavakolpour S; Mahmoudi H; Balighi K; Abedini R; Daneshpazhooh M
    Int Immunopharmacol; 2018 Jan; 54():131-138. PubMed ID: 29132070
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
    Londhe PJ; Kalyanpad Y; Khopkar US
    Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Two cases of cutaneous-type pemphigus vulgaris and a case of pemphigus foliaceus without mucosal involvement despite high anti-desmoglein 3 autoantibody levels.
    Terada A; Akasaka E; Nakano H; Sawamura D
    J Dermatol; 2023 Nov; 50(11):1501-1505. PubMed ID: 37485682
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris.
    Tovanabutra N; Bax CE; Feng R; Kushner CJ; Payne AS
    J Invest Dermatol; 2022 Apr; 142(4):1058-1064.e7. PubMed ID: 34710389
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy.
    Cho YT; Huang YM; Wang LF; Chu CY
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):230-237. PubMed ID: 31103376
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pemphigus Vegetans of Hallopeau: A Case Report.
    Maljić J; Radoš J; Lončarić D; Lakoš Jukić I
    Acta Dermatovenerol Croat; 2023 Aug; 31(1):43-44. PubMed ID: 37843091
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Grover's Disease in a Kidney Transplant Recipient.
    Kirincich J; Lončarić D; Bukvić Mokos Z; Bašić-Jukić N
    Acta Dermatovenerol Croat; 2019 Sep; 27(3):192-194. PubMed ID: 31542066
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Detection of serum desmoglein antibody level using enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with pemphigus vulgaris].
    Zhong S; Qiu YF; Han BB; Zhao JY; Zhu XJ; Chen XX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 43(3):414-5. PubMed ID: 21681274
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up.
    Aberer W; Wolff-Schreiner EC; Stingl G; Wolff K
    J Am Acad Dermatol; 1987 Mar; 16(3 Pt 1):527-33. PubMed ID: 3819096
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
    Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
    Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience.
    Snast I; Spitzer L; Hodak E; Levi A; Mimouni D; Leshem YA
    Dermatology; 2021; 237(2):179-184. PubMed ID: 32756069
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice.
    Hofrichter M; Dworschak J; Emtenani S; Langenhan J; Weiß F; Komorowski L; Zillikens D; Stöcker W; Probst C; Schmidt E; Goletz S
    Front Immunol; 2018; 9():1935. PubMed ID: 30233569
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus.
    Maho-Vaillant M; Perals C; Golinski ML; Hébert V; Caillot F; Mignard C; Riou G; Petit M; Viguier M; Hertl M; Boyer O; Calbo S; Fazilleau N; Joly P
    J Invest Dermatol; 2021 Sep; 141(9):2132-2140.e1. PubMed ID: 33766510
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Therapy of pemphigus].
    van Beek N; Zillikens D; Schmidt E
    Hautarzt; 2019 Apr; 70(4):243-253. PubMed ID: 30887081
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pemphigus vulgaris relapse during the coronavirus disease pandemic.
    Saleh MA; Saleh NA
    Dermatol Ther; 2022 Apr; 35(4):e15354. PubMed ID: 35108427
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.
    Hammers CM; Chen J; Lin C; Kacir S; Siegel DL; Payne AS; Stanley JR
    J Invest Dermatol; 2015 Mar; 135(3):742-749. PubMed ID: 25142730
    [TBL] [Abstract][Full Text] [Related]  

  • 79. COVID outcome in pemphigus: Does rituximab make pemphigus patients susceptible to more severe COVID-19?
    Aryanian Z; Balighi K; Sajad B; Esmaeli N; Daneshpazhooh M; Mazloumi Tootoonchi N; Beigmohammadi F; Mohseni Afshar Z; Hatami P
    J Cosmet Dermatol; 2023 Nov; 22(11):2880-2888. PubMed ID: 37573477
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.